Chronic heart failure: An overview of conventional treatment versus novel approaches

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 12, 2005, Pages 628-638

  Landmesser, Ulf ^a   Drexler, Helmut ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic heart failure; Device therapy; Medical therapy; Stem cells; Surgical therapy

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CANDESARTAN; CARDIAC GLYCOSIDE; CONIVAPTAN; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENALAPRIL; EPLERENONE; ERYTHROPOIETIN; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; LEVOSIMENDAN; METOPROLOL; NEBIVOLOL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXIPURINOL; PLACEBO; ROSUVASTATIN; SPIRONOLACTONE; TOLVAPTAN; UNINDEXED DRUG; VALSARTAN; VASOPRESSIN ANTAGONIST;

ADD ON THERAPY; ARTIFICIAL HEART PACEMAKER; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; DRUG DOSE REGIMEN; GYNECOMASTIA; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; HYPERKALEMIA; KINESIOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; QRS COMPLEX; REVIEW; STEM CELL TRANSPLANTATION; SURGICAL APPROACH;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; APOPTOSIS; CARDIAC GLYCOSIDES; ERYTHROPOIETIN; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXIDATIVE STRESS; PACEMAKER, ARTIFICIAL; SPIRONOLACTONE; STROKE VOLUME; TETRAZOLES; VALINE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 29544433224     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0371     Document Type: Review

References (67)

1. Garg R and Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273: 1450-1456
2. Granger CB et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 362: 772-776
3. Cohn JN et al. (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675
4. Gheorghiade M et al. (2003) β-blockers in chronic heart failure. Circulation 107: 1570-1575
5. Bristow MR (2000) β-adrenergic receptor blockade in chronic heart failure. Circulation 101: 558-569
6. The Beta-Blocker Evaluation of Survival Trial Investigators (2001) A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344: 1659-1667
7. Bristow MR et al. (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94: 2807-2816
8. Wikstrand J et al.; Merit-HF Study Group (2002) Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: Analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 40: 491-498
9. Simon T et al. (2003) Bisoprolol dose-response relationship in patients with congestive heart failure: A subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J 24: 552-559
10. Pitt B et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717
11. Juurlink DN (2004) et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543-551
12. McMurray JJ et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 362: 767-771
13. Pfeffer MA et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906
14. Katada J et al. (2005) Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation 111: 2157-2164
15. Khand AU et al. (2003) Khand AU Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 42:1944-1951
16. The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525-533
17. Rathore SS et al. (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289: 871-878
18. Rathore SS et al. (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347: 1403-1411
19. Taylor AL et al.; African-American Heart Failure Trial Investigators (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351: 2049-2057
20. Carson P et al. (1999) Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5: 178-187
21. Redfield MM et al. (2003) Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 289: 194-202
22. Yusuf S et al. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 362: 777-781
23. Flather MD et al. (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26: 215-225
24. Pina IL et al. (2003) Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation 107: 1210-1225
25. Bristow MR et al. for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350: 2140-2150
26. Cleland JG et al. for the Cardiac Resynchronization - Heart Failure (CARE-HF) Study Investigators (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352: 1539-1549
27. Bardy GH et al. (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352: 225-237
28. Rose EA et al. for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group (2001) Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345: 1435-1443
29. Bauersachs J et al. (2001) Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104: 982-985
30. Landmesser U et al. (2004) Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, LV function and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110: 1933-1939
31. Node K et al. (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108: 839-843
32. Landmesser U et al. (2005) Simvastatin versus Ezetimibe: Pleiotropic and lipid lowering effects on endothelial function in humans. Circulation 111: 2356-2363
33. Horwich TB et al. (2004) Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardio 43: 642-648
34. Rauchhaus M et al. (2003) The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 42: 1933-1940
35. Francis GS et al. (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82: 1724-1729
36. 2-receptor blockade with tolvaptan in patients with chronic heart failure. Circulation 107: 2690-2696
37. Gheorghiade M et al. (2004) Effects of tolvaptan vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA 291: 1963-1971
38. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104: 2417-2423
39. Russell SD et al. (2003) Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am Heart J 145: 179-186
40. Gheorghiade M et al. (2005) Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 11: 260-269
41. Hare JM et al. (2005) NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 115: 509-517
42. Landmesser U et al. (2002) Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: Role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106: 3073-3078
43. Cappola TP et al. (2001) Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104: 2407-2411
44. Doehner W et al. (2002) Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: Results from 2 placebo-controlled studies. Circulation 105: 2619-2624
45. Engberding N et al. (2004) Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: A new action for an old drug? Circulation 110: 2175-2179
46. Stull LB et al. (2004) Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 95: 1005-1011
47. Freudenberger RS et al. (2004) Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III - IV congestive heart failure. Expert Opin Investig Drugs 13: 1509-1516
48. Ezekowitz JA et al. (2003) Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107: 223-225
49. Mancini DM et al. (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107: 294-299
50. Silverberg DS et al. (2003) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardiol 37: 1775-1780
51. Parsa CJ et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999-1007
52. Calvillo L et al. (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100: 4802-4806
53. Bahlmann FH et al. (2004) Erythropoietin regulates endothelial progenitor cells. Blood 103: 921-926
54. Drexler H and Hassenfuss G (2003) Physiology of the normal and failing heart. In Cardiology, 829-844 edn 2 (Eds Crawford MH et al.) London: WJ Mosby
55. del Monte F et al. (2003) Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol 546: 49-61
56. Hoshijima M et al. (2002) Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8: 864-871
57. Schmitt JP et al. (2003) Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299: 1410-1413
58. Follath F et al. (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 360: 196-202
59. Wencker D et al. (2003) A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 111: 1497-1504
60. Limbourg FP et al. (2005) Bone marrow stem cells for myocardial infarction: Effector or mediator? Circ Res 96: 6-8
61. Menasché P et al. (2001) Myoblast transplantation for heart failure. Lancet 357: 279-280
62. Wollert KC et al. (2005) Clinical applications of stem cells for the heart. Circ Res 96: 151-163
63. Assmus B et al. (2004) Transcoronary transplantation of progenitor cells and recovery of left ventricular function in patients with chronic ischemic heart disease: Results of a randomized, controlled trial. Circulation 110 (Suppl III): S238
64. Perin EC et al. (2004) Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 110 (Suppl 1): SII213-SII218
65. Sabbah HN et al. (2003) Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ Res 93: 1095-1101
66. Mann DL et al.; Acorn Investigators and Study Coordinators (2004) Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. J Card Fail 10: 185-192
67. Wu AH et al. (2005) Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 45: 381-387